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ABSTRACT
Antimicrobial peptides represent an important component of the innate immune defenses of living or-
ganisms, including humans. They are broad-spectrum surface-acting agents secreted by the epithelial cells 
of the body in response to infection. Recently, L-isoleucine and its analogues have been found to induce 
antimicrobial peptides. The objectives of the study were to examine if addition of L-isoleucine to oral rehy-
dration salts (ORS) solution would reduce stool output and/or duration of acute diarrhoea in children and 
induce antimicrobial peptides in intestine. This double-blind randomized controlled trial was conducted 
at the Dhaka Hospital of ICDDR,B. Fifty male children, aged 6-36 months, with acute diarrhoea and some 
dehydration, attending the hospital, were included in the study. Twenty-five children received L-isoleucine 
(2 g/L)-added ORS (study), and 25 received ORS without L-isoleucine (control). Stool weight, ORS intake, 
and duration of diarrhoea were the primary outcomes. There was a trend in reduction in mean±standard 
deviation (SD) daily stool output (g) of children in the L-isoleucine group from day 2 but it was significant 
on day 3 (388±261 vs 653±446; the difference between mean [95% confidence interval (CI) (-)265 (-509, 
-20); p=0.035]. Although the cumulative stool output from day 1 to day 3 reduced by 26% in the isoleucine 
group, it was not significant. Also, there was a trend in reduction in the mean±SD intake of ORS solution 
(mL) in the L-isoleucine group but it was significant only on day 1 (410±169 vs 564±301), the difference 
between mean (95% CI) (-)154 (-288, -18); p=0.04. The duration (hours) of diarrhoea was similar in both 
the groups. A gradual increase in stool concentrations of ß-defensin 2 and 3 was noted but they were not 
significantly different between the groups. L-isoleucine-supplemented ORS might be beneficial in reduc-
ing stool output and ORS intake in children with acute watery diarrhoea. A further study is warranted to 
substantiate the therapeutic effect of L-isoleucine.
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solutions; Randomized controlled trials; Bangladesh
INTRODUCTION
Globally, diarrhoea still accounts for 1.6-2.5 million 
deaths each year; children in the developing world 
experience  an  average  of  three  episodes  of  diar-
rhoea each year; and despite the impressive decline 
from 1980, it remains the second leading cause of 
childhood  deaths  (1).  Most  important  elements 
of the management of acute diarrhoea include: 
(a) prevention of dehydration using home-made 
fluids or oral rehydration salts (ORS) solution; (b) 
correction of dehydration using ORS solution or 
intravenous fluid, as clinically indicated; (c) replac-
ing ongoing stool losses followed by oral mainte-
nance fluid; and d) continuation of usual food, 
including breastfeeding. Antimicrobial therapy 
is recommended in the management of diarrhoea 
caused by a few specific pathogens, such as severe 
cholera, shigellosis, invasive intestinal amoebiasis, 
and symptomatic giardiasis. The cost of therapy Alam NH et al. L-isoleucine-added ORS in acute diarrhoea
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and, more importantly, the emergence of resistant 
pathogens are the major concerns for antimicrobial 
therapy for diarrhoea as it is for other bacterial in-
fections. A major limitation of ORS—old formula-
tion (Na-90 mmol/L, Cl-80 mmol/L, K-20 mmol/L, 
citrate-10 mmol/L, glucose anhydrous-111 mmol/
L, total osmolarity 311 mosmol) (including current 
ORS: Na-75 mmol/L, Cl-65 mmol/L, K-20 mmol/L, 
citrate-10 mmol/L, glucose, anhydrous-75 mmol/
L, total osmolarity 245-mosmol/L) is that it nei-
ther reduces the duration of diarrhoea nor its sever-
ity, and efforts are, thus, continuing to overcome 
these  limitations  by  developing  newer  formula-
tions of ORS (2-7).
Antimicrobial peptides represent an important 
component of the innate immune defenses of or-
ganisms ranging from plants to insects to humans. 
They are membrane-active agents that kill microbes 
by various mechanisms (8,9). Most have a broad 
spectrum of activities that include bacteria, viruses, 
and fungi. In humans, two major classes of antimi-
crobial peptides—defensins and cathelicidins (LL-
37)—have been described. The human defensins 
are of two types: α- and ß-defensins. α-defensins 
are mostly present in neutrophil granules neces-
sary for non-oxidative killing of phagocytosed mi-
crobes and those in the Paneth cells in the crypts of 
Leiberkuhn in the small intestine (10). ß-defensins, 
present in virtually all epithelial surfaces, includ-
ing those of the skin, airways, gut, and urogenital 
tracts (11-14), contribute to the antimicrobial barri-
er at the epithelial surface. Impairment of defensin 
functions increases susceptibility to infection of the 
airway in cystic fibrosis (15) and enhances Salmo-
nella infection in the intestinal tract of mouse (16). 
Many antimicrobial peptides expressed on epithe-
lial surfaces are induced in the settings of infection 
or injury (8,9). Pattern-recognition receptors (17) 
likely play a critical role in this process as has been 
shown in CD-14-mediated induction of ß-defen-
sins by bacterial lipopolysaccharide (18). Whole, 
heat-killed bacteria and fungi induce human ß-de-
fensins (HBD)-2 in human keratinocytes but the 
molecular basis of this response is not understood 
(19). Inflammatory cytokines also induce epithelial 
ß-defensins (20-22). Pharmacological induction of 
antimicrobial peptides at epithelial barriers could 
have therapeutic utility (23,24). Several groups 
have recently reported the discovery of substances 
with low molecular weight that induce epithelial 
antimicrobial peptides in cell-based assays (23,24). 
L-isoleucine and its analogues are highly-specific 
ß-defensin inducers in epithelial cells (24,25). Bu-
tyrate has also been shown to induce antimicrobial 
peptides in the colonic epithelial cells and has been 
shown to exhibit therapeutic benefit in a rabbit 
model of shigellosis (23); however, it cannot be ad-
ministered orally as such for its foul smell. 
In this pilot study, we have evaluated orally-ad-
ministered L-isoleucine in the treatment of acute 
infectious diarrhoea in infants and young children. 
The study was driven by the hypothesis that L-iso-
leucine enhances the secretion of antimicrobial 
peptides in the intestinal epithelium and might 
favourably impact the resolution of disease. There-
fore, we undertook a study to determine whether 
the use of L-isoleucine-supplemented ORS solution 
would enhance clinical recovery of children with 
acute watery diarrhoea and whether the treatment 
could be correlated with the presence of increased 
concentrations of antimicrobial peptides in stool. 
MATERIALS AND METHODS
Study design
In this pilot randomized, double-blind controlled 
clinical trial, we enrolled 50 infants and young 
children—25 in the study group and 25 in the con-
trol group. The study patients were selected from 
among male children, aged 6-36 months, who at-
tended the Dhaka Hospital of ICDDR,B during July 
2007–June 2008, with a history of acute watery di-
arrhoea of less than 48 hours’ duration with some 
dehydration. Those with cholera (stool dark-field 
microscopy positive for Vibrio cholerae), dysentery 
(presence of visible blood in stool), severe dehydra-
tion, severe malnutrition (weight-for-age <60% or 
weight-for-length <70% of the National Center for 
Health Statistics median or with nutritional oe-
dema), and history of taking antimicrobial or an-
tidiarrhoeal drugs for the current illness were not 
eligible. 
Patient management and treatment  
schedule
Children fulfilling the eligibility criteria were ad-
mitted to the study ward of the Dhaka Hospital 
of ICDDR,B and weighed. Their detailed medical 
history was obtained. A thorough physical exami-
nation, including assessment of dehydration, was 
done. All findings were recorded in pre-designed 
Case Report Forms (CRFs). The status of dehydra-
tion was assessed following the guidelines of the 
World Health Organization (WHO) (26). Children 
were then randomized to receive either: (a) WHO- 
and United Nations Children’s Fund-recommended 
hypo-osmolar glucose-ORS (Na-75 mmol/L, Cl-65 
mmol/L, K-20 mmol/L, citrate-10 mmol/L, and glu-Alam NH et al. L-isoleucine-added ORS in acute diarrhoea
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cose-75 mmol/L) plus L-isoleucine-2 g/L-calculated 
osmolality–252 mosmol/L (study group), or (b) the 
same ORS without L-isoleucine (control group). 
The dose of L-isoleucine was arbitrarily selected. 
A trained staff member of ICDDR,B, not involved 
in the study, prepared the randomization list. The 
name of intervention was indicated on a paper, 
kept inside the envelope. The sealed envelopes 
were supplied to the Dhaka Hospital pharmacists, 
not involved in the study in any way, to prepare 
the solutions, which were identical in appearance 
and similar in taste. They labelled the bottles with 
the assigned random number, patient’s name, and 
hospital registration number and handed these 
over to the study staff for making ready to drink. 
L-Isoleucine is a chemically- and physically-stable 
and neutral amino acid, tasteless, and colourless at 
the concentration used in ORS (http://www.ajiami-
noacids.com/default.aspx). After 12 hours, unused 
ORS was measured and discarded, and a fresh bottle 
of ORS was prepared for continuation of therapy, 
if required. Oral rehydration therapy (ORT) was 
continued until resolution of diarrhoea but up to a 
maximum of five days. All children received zinc 
tablet. Infants, aged 6-12 months, received 10 mg 
daily, and children, aged over 12 months, received 
20 mg daily for 10 days. Children on breastmilk 
was allowed to receive breastmilk, and supplemen-
tary diet prepared from cows’ milk, rice-powder, 
and sugar (milk suji) delivering 78 kcal/100 g was 
administered to those aged over six months (10 
mL/kg every two hours for at least 10 feeds) follow-
ing the standard practice of the hospital.
Laboratory investigations 
Routine laboratory investigations included micro-
scopic examination of fresh stool specimens for 
enumeration of leucocytes and red blood cells and 
identification of parasites, such as Giardia lamblia, 
Entamoeba  histolytica,  and  Cryptosporidium,  and  for 
culture to isolate and identify Salmomella, Shigella, 
V. cholerae, and Campylobacter jejuni by standard 
methods and for enzyme-linked immunosorbent as-
say (ELISA) to demonstrate the presence of rotavirus. 
Clinical assessments
The children were placed on a ‘cholera-cot’, and a 
paediatric urine-collector (PUC bag) was used for 
collecting urine separately. Stool-weight, supple-
mented food, and body-weight were measured 
with an electronic scale (Sartorius, Göttingen, Ger-
many) with a precision of 1 g. ORS, plain water, 
and urine were measured with a calibrated cylinder. 
Measurements of all intakes (ORS, food, and water) 
and output (stool, urine, and vomit) were summa-
rized for every six-hour period of the study until 
discharge. Body-weight was also measured every 
six hours until the children were discharged. Physi-
cal examinations were performed in the morning 
and in the afternoon. Resolution of diarrhoea was 
defined as the appearance of soft or formed stool 
or no stool for 12 hours. The participating patients 
were discharged after the resolution of diarrhoea 
but not before 72 hours. Therapeutic success was 
defined as cessation of diarrhoea within five days of 
the study intervention. The duration of diarrhoea 
was calculated from the time of randomization to 
the last watery stool. 
Assessments of antimicrobial peptides in 
stool
Stool specimen (approximately 3-5 g) from each 
patient was collected at the end of each 24-hour 
study period, mixed with a buffer containing 60% 
acetonitrile and 10% trifluoroacetic acid in water 
in a ratio of 1:10, mixed vigorously, kept overnight 
at 4 °C in a shaking incubator, and centrifuged at 
13,000 rpm for 30 minutes. Supernatant was filtered 
with 0.2 µm filter, lyophilized, and stored at -20 °C 
until used. Before using in ELISA, lyophilized stool 
was dissolved in phosphate buffered saline (PBS) in 
one-third of the starting volume (27). Cathelicidin 
LL-37 was measured in stool by ELISA as described 
earlier (28). ELISA plates (Maxisorp by Nunc, Na-
perville, IL, USA) were coated with monoclonal LL-
37 antibody (5 µg/mL in coating buffer, pH=9.6) 
at 4 °C overnight. After washing, 0.1% gelatin in 
PBS was added to block unspecific binding for one 
hour at room temperature. Samples or standard LL-
37 peptide, in a serial dilution (0.1-1,000 ng/mL in 
PBS), were added in duplicate and incubated at 4 °C 
overnight, followed by incubation with biotinyl-
ated polyclonal LL-37 antibody (20 µg/mL; 0.1% 
gelatin in PBS) at room temperature for two hours 
and incubation with streptavidin-AP (1:2000; 0.1% 
gelatin in PBS) at room temperature for two hours. 
Between the incubations, plates were washed three 
times with PBS (0.05% Tween). Finally, plate was 
developed with p-nitrophenylphosphate (l mg/
mL) in diethanolamin buffer (pH=9.8), and the 
absorbance was measured at 405 nm after 30–60 
minutes. ß-defensin (HBD) 1 and 3 were measured 
in stool extracts using ELISA kits (Phoenix Phar-
maceuticals, Inc., Burlingame, CA) following the 
instructions of the manufacturer.
Analysis of data
Data were analyzed using the SPSS PC+ software Alam NH et al. L-isoleucine-added ORS in acute diarrhoea
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(version 10) (University of Chicago, USA). Contin-
uous variables were compared between the groups 
with Student’s t-test, and χ2 was used for compar-
ing the dichotomous variables. A survival plot was 
constructed and compared with log rank rest. Data 
were not normally distributed, such as antimicro-
bial peptides (HBD-2 and HBD-3) transformed into 
square root, and analysis was performed with two-
way analysis of variance (ANOVA).
Ethical issues
Written, informed consent was obtained from 
parents or the legal guardians of each of the study 
children. The Research Review Committee and the 
Ethical Review Committee of ICDDR,B approved 
the study protocol.
RESULTS
Effects of treatment on clinical response 
Since this is an exploratory pilot study, we stud-
ied 50 patients—25 received L-isoleucine-supple-
mented ORS (L-isoleucine group), and 25 received 
ORS without L-isoleucine (control group). Baseline 
clinical characteristics, such as age, body-weight, 
weight-for-length (%) of NCHS median, weight-for-
age (%) of NCHS median, duration of diarrhoea be-
fore admission, duration of vomiting before admis-
sion, dehydration status, breastfeeding status, etc., 
were comparable between the groups (Table 1). The 
major outcome variables were stool output, ORS 
intake, and duration of diarrhoea. With respect to 
stool output, we noted a trend in reduced output 
in children receiving ORS supplemented with L-
isoleucine on day 1, which continued on day 2 and 
became statistically significant (p=0.03) on day 3 
(Table 2). Also, we observed a trend in reductions 
in the volume of ORS intake in the L-isoleucine 
group compared to the control group, although 
statistical significance (p=0.04) was only observed 
on day 1. These findings may be due to the small 
sample-size. We did not observe a reduction in the 
duration of diarrhoea in children receiving L-iso-
leucine-supplemented ORS (Table 2). Kaplan Meier 
survival plot (Fig.) for duration of diarrhoea also 
failed to detect any significant difference between 
the groups. There were no adverse effects associated 
with the intake of L-isoleucine-supplemented ORS.
Effects of treatment on ß-defensin levels in 
stool
We measured the stool concentrations of four an-
timicrobial peptides (LL-37, HBD-1, HBD-2, and 
HBD-3) expressed in the lumen of small and large 
intestines. Measurements were made at the start of 
treatment (day 0), after two days of treatment (day 
2), and after diarrhoea had resolved (day 7). Stool 
sample for day 7 was collected as ambulatory. LL-37 
peptide measured in stool samples was barely de-
tectable in most patients. Two-way ANOVA did not 
show any difference in stool LL-37 levels between 
days (p=0.47) or treatment groups (p=0.10) (data 
not shown). Concentrations of HBD-1 in stool 
were barely detectable and were similar in both 
Table 1. Baseline characteristics of study children 
Variable
Isoleucine-added 
ORS group (n=25)
Control ORS 
group (n=25)
p value
Age (months) 10.4±3 12.0±4.5 0.12
Body-weight ( kg) 7.7±1.0 8.0±1.14 0.36
Weight-for-age (%) 81.0±8.2 79.5±10.6 0.59
Weight-for-length (%) 87.4±8.3 88.1±9.0 0.76
Duration (hours) of diarrhoea before admission  28.0±11.5 27.9±13.5 0.95
Number of stools in the last 24 hours 12±4 11±4 0.88
Duration (hours) of vomiting 
before admission  26.9±13.0 24.6±15 0.56
Number of vomits in the last 24 hour 7.5±3 7.5±4 0.98
Breastfeeding (yes/no) 24/2 22/3 0.67
Dehydration status (none/some) 0/26 0/25
Fever before admission (yes/no) 14/12 10/15 0.57
Stool pathogens isolated
Enterotoxigenic Eschericia coli 
Rotavirus 
3
18
3
17
0.72
Figures represent mean±SD or numbers. ORS=Oral rehydration solutions; SD=Standard deviationAlam NH et al. L-isoleucine-added ORS in acute diarrhoea
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the groups of patients. Concentrations of HBD-2 in 
stool increased significantly in both the groups be-
tween days (p=0.0001) but no difference between 
treatment groups could be observed (p=0.5). Con-
centrations of HBD-3 in stool, however, increased 
significantly (p=0.017) in the intervention group 
from day 2 to day 7 but showed no consistent pat-
tern in the control group. Two-way ANOVA showed 
a significant difference (p=0.02) between days but 
not between treatment groups (p=0.51). However, 
there were interactions that showed a trend for sig-
nificance (p=0.08) (Table 3). Within day 7, concen-
tration of HBD-3 was significantly higher (p=0.027) 
in the isoleucine group compared to the control 
group. 
DISCUSSION
The results of this pilot study demonstrated that 
L-isoleucine-supplemented ORS showed some 
beneficial effects in terms of reducing stool output 
and ORS intake in children with non-cholera acute 
watery diarrhoea compared to the control group, 
albeit without the anticipated shortening of its du-
ration. To our knowledge, this is the first study that 
evaluated the effect of L-isoleucine-added ORS on 
stool output and recovery in patients with acute 
non-cholera diarrhoea. Some studies have, how-
ever, evaluated the effect of other amino acids, e.g. 
alanine, glycine, and glutamine, added to ORS in 
the treatment of infectious diarrhoeas (2-5). Some 
of these studies have shown beneficial effects in 
terms of reducing stool output while these ORSs 
were used in cholera patients but those amino acids- 
supplemented ORSs had no significant impact 
when used for the treatment of acute non-cholera 
diarrhoea in young children. The amino acids, such 
as alanine, glycine, and glutamine, were thought to 
enhance absorption of sodium and water from the 
Table 2. Comparison of outcome variables 
Variable
Isoleucine-add-
ed ORS group 
(n=25)
Control ORS 
group (n=25) 
Difference between 
mean (95% CI) 
p value 
 
Stool output (g)—day 1  560±240 563±409 -3.0 (-189,183) 0.94
Stool output (g)—day 2  407±284 515±316 -108 (-285, 71) 0.23
Stool output (g)—day 3  388±261 653±446 -265 (-509, -20) 0.035
ORS intake (mL)—day 1  410±169 564±301 -154 (-288, -18) 0.04
ORS intake (mL)—day 2 330±245 401±226 -71 (-212, 70) 0.23
ORS intake (mL)—day 3  312±233 454±260 -142 (-312, 28) 0.09
Duration (hours) of diarrhoea  74±38 75±42 -1 (-17, 25) 0.96
Figures represent mean±SD. CI=Confidence interval; ORS=Oral rehydration solution; SD=Standard deviation
Fig. Kaplan-Meir survival curve for duration of diarrhoea
ORS=Oral rehydration solution 
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small intestine when added to ORS. Whether L-iso-
leucine can also enhance absorption of sodium and 
water in our study patients in the small intestine 
and, in so doing, reduce stool output, was not in-
vestigated in the present study. Further studies may 
establish the effect of antimicrobial peptides by any 
agents blocking their effect. 
We postulated that supplementation with L-isoleu-
cine would induce antimicrobial peptides in the 
intestine that would have activities against enteric 
bacteria and viruses. Of the antimicrobial peptides 
measured in the present study, HBD-3 exhibited 
an increase in stool concentrations over the days 
in the L-isoleucine-supplemented group, although 
there was a non-significant difference between the 
two groups. We did not see any significant differ-
ence in the concentrations of LL-37, HBD-1, and 
HBD-2 between the two groups. 
HBD-3 is inducible and is expressed by small in-
testinal and colonic epithelial cells, particularly in 
the crypt regions, in addition to their direct anti-
microbial activities; ß-defensins are chemotactic 
for memory T cells and dendritic cells, suggesting 
that they play an important role in the integra-
tion of the innate and acquired immune responses 
(16). Upregulation of HBD-3 by isoleucine may ad-
ditionally play a role in immune modulation in 
acute watery diarrhoea. Isoleucine is essential for 
normal growth and differentiation of enterocytes 
and keratinocytes, and treatment with isoleucine 
may, thus, support epithelial cell regeneration dur-
ing diarrhoea.
Limitations 
Our study has several limitations. The bacterial 
and viral load in stool was not determined to show 
bacterial/viral clearance from stool after treatment. 
The epithelial expression of the antimicrobial pep-
tides in the small intestine was not assessed; re-
lease of peptides in stool is a total output from the 
total gut. We did not assess whether the released 
HBD-2 or HBD-3 peptides were in active form or 
pro-form. The study being an exploratory pilot one 
had a small sample-size that might have been in-
adequately powered to distinguish several param-
eters measured between the groups, for which only 
a trend was observed. We selected a single low-dose 
(arbitrarily) of isoleucine on the basis of safety for 
this first study and did not explore the effects of 
higher doses. 
Conclusions
This preliminary study opens a new field of re-
search—the clinical study of chemically simple, 
inexpensive, and safe substance to induce endoge-
nous antimicrobial peptides to achieve a therapeu-
tic benefit in an infectious disease. We anticipate 
that such agents should they prove effective would 
have applications in the prevention and treatment 
of infectious diseases and could reduce the use of 
conventional antibiotics. 
What is already known on this topic 
Antimicrobial peptides secreted from the epithelial 
surfaces of all living animals and plants represent 
an important component of the innate immune 
defenses of organisms. They are membrane-active 
agents that kill microbes by various mechanisms. 
Recently, L-isoleucine and its analogues have been 
reported to induce antimicrobial peptides in epi-
thelial surfaces of the intestine. However, its thera-
peutic potential has not been evaluated. 
What this study adds 
So far, this is the first study that has evaluated the 
therapeutic effect of L-isoleucine added to ORS in 
the treatment of acute diarrhoea in children. Al-
Table 3. Concentration of beta-defensin-3 (HBD-3) and beta-defensin-2 ( HBD-2) in stool from patients 
treated with or without L-isoleucine in oral rehydration solution
Antimicrobial 
peptide 
 Time    Control Supplemented Two-way ANOVA p value
HBD-3 Day 0 238±12 37±0 Time 0.023
Day 2 37±0 62±1 Supplement 0.518
Day 7 153±6 51±24 Interaction 0.080
HBD-2 Day 0 9±5 44±18 Time 0.001
Day 2 39±9 63±11 Supplement 0.56
Day 7 123±41 132±28 Interaction 0.62
Data expressed as mean±standard deviation. Concentration of beta-defensin-3 and beta-defensin-2 in 
stool is expressed in pg/g stool. ANOVA=Analysis of varianceAlam NH et al. L-isoleucine-added ORS in acute diarrhoea
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though this is the pilot and exploratory study, the 
preliminary results showed some beneficial effects 
in terms of reduction of stool output and ORS in-
take. Although induction of antimicrobial peptides 
in response to L-isoleucine was not significantly 
increased compared to the control, there were in-
dications. Thus, we recommend more mechanistic 
studies to establish the therapeutic and antimicro-
bial-inducing effect of L-isoleucine. 
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